en · de · es · fr · pt
sermorelin-notes.peptides9002.com › Data › Bremelanotide Identity And Background — Reference Sheet

Bremelanotide Identity And Background — Reference Sheet

By Editorial Desk · published 2025-10-18 · last reviewed 2025-11-10 · Data

The short version of melanocortin analogue fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-11-10 and is reviewed periodically as new material appears.

Bremelanotide Identity and Background

Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.

Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.

The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.

Background and Receptor Pharmacology

Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.

Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.

Pt-141 at a glance

PropertyValueNotes
Molecular formulaC50H68N14O10Cyclic heptapeptide backbone
Molecular massApproximately 1025 DaNominal mass of the free peptide
AppearanceWhite to off-white lyophilised powderTypical for purified synthetic peptides
Solubility classFreely soluble in waterOrganic solubility is limited
Typical storage temperature−20 °C or belowProtect from moisture and light

Storage Stability and Analytical Methods

Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.

Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.

Related pages on this site

Peptide Handling and Storage Practice

Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.

Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.

Further detail

The recognised metalloids have either pyrotechnic applications or associated properties. Boron and silicon are commonly encountered; they act somewhat like metal fuels. Boron is used in pyrotechnic initiator compositions (for igniting other hard-to-start compositions), and in delay compositions that burn at a constant rate. Boron carbide has been identified as a possible replacement for more toxic barium or hexachloroethane mixtures in smoke munitions, signal flares, and fireworks. Silicon, like boron, is a component of initiator and delay mixtures. Doped germanium can act as a variable speed thermite fuel. Arsenic trisulfide As2S3 was used in old naval signal lights; in fireworks to make white stars; in yellow smoke screen mixtures; and in initiator compositions. Antimony trisulfide Sb2S3 is found in white-light fireworks and in flash and sound mixtures. Tellurium has been used in delay mixtures and in blasting cap initiator compositions. Carbon, aluminium, phosphorus, and selenium continue the theme. Carbon, in black powder, is a constituent of fireworks rocket propellants, bursting charges, and effects mixtures, and military delay fuses and igniters. Aluminium is a common pyrotechnic ingredient, and is widely employed for its capacity to generate light and heat, including in thermite mixtures. Phosphorus can be found in smoke and incendiary munitions, paper caps used in toy guns, and party poppers. Selenium has been used in the same way as tellurium.

== History == LFTs derive from paper chromatography, which was developed in 1943 by Martin and Synge, and elaborated in 1944 by Consden, Gordon and Martin. There was an explosion of activity in this field after 1945. The ELISA technology was developed in 1971. A set of LFT patents, including the litigated US 6,485,982 described below, were filed by Armkel LLC starting in 1988. The first commercially available lateral flow device was Unipath's Clearblue One Step in 1988. This product combined Paired Monoclonal Antibody technology (patented in 1980 by Unipath's Prof. Philip Porter and colleagues including Paul Davis and Keith May) and the original Clearblue product launched in June 1985.

== Description == The Red Savina typically measures 2 inches by 1.5 inches (5 x 3.5 cm), and is described by cultivators as a "wrinkled" fruit with a "Chinese lantern" shape. Unlike a conventional orange habanero, the Red Savina is distinctively dark red, and may have been bred using spicy red mutations of habanero. Until 2011, it was protected by the U.S. Plant Variety Protection Act (PVP #9200255).

== Research == Her achievements include the discovery of adaptins, which are specific proteins that manage cell-trafficking to ensure the correct cell cargo is transported to the right location. She also discovered different combinations of adapting, when together with clathrin, form a coat around vesicles that bud from intracellular membranes and act as transporters for protein packages to be distributed in the cell. She also developed the technique "knock sideways," which inactivates proteins in seconds. After finishing her postdoc, she was able to start her own lab. Her main focus was to learn more about the AP protein in depth. She had to also work with DNA because in order to characterize the complexes thoroughly, she needed to clone the subunits. Robinson and her lab managed to find another AP complex, AP-3, which interacts with lysosomal membrane proteins such as LAMP1. AP-3 also interacts with tyrosinase, which is a key enzyme in melanin biosynthesis, so AP-3 is important for tyrosinase trafficking to premelanosomes. As of 2016 Robinson has a lab at Cambridge Institute for Medical Research. She specifically works with coated vesicles. The best-characterized coated vesicles are the clathrin-coated vesicles (CCVs). The coats on CCVs are primarily of clathrin, adaptor protein (AP) complexes, and alternative adaptors. Her working hypothesis is that for each trafficking pathway, there are a number of different adaptors, each of which is recruited independently onto the appropriate membrane.

Sources: en.wikipedia.org

Background from the literature

=== Microchimerism === Microchimerism of fetal cells (offspring lymphoid cells in maternal circulation) may generate autoimmunity in women who have previously been pregnant. Generation of an autoimmune potential via microchimerism may lead to a switch from a silent form of autoimmunity with age-dependent decrease in self-tolerance.

While most causes of sudden cardiac death relate to congenital or acquired cardiovascular disease, an exception is commotio cordis, in which the heart is structurally normal but a potentially fatal loss of rhythm occurs because of the accident of timing of a blow to the chest. Its fatality rate is about 65% even with prompt CPR and defibrillation, and more than 80% without.

The most common cause of a myocardial infarction is the rupture of an atherosclerotic plaque on an artery supplying heart muscle. Plaques can become unstable, rupture, and additionally promote the formation of a blood clot that blocks the artery; this can occur in minutes. Blockage of an artery can lead to tissue death in tissue being supplied by that artery. Atherosclerotic plaques are often present for decades before they result in symptoms. The gradual buildup of cholesterol and fibrous tissue in plaques in the wall of the coronary arteries or other arteries, typically over decades, is termed atherosclerosis. Atherosclerosis is characterized by progressive inflammation of the walls of the arteries. Inflammatory cells, particularly macrophages, move into affected arterial walls. Over time, they become laden with cholesterol products, particularly LDL, and become foam cells. A cholesterol core forms as foam cells die. In response to growth factors secreted by macrophages, smooth muscle and other cells move into the plaque and act to stabilize it. A stable plaque may have a thick fibrous cap with calcification. If there is ongoing inflammation, the cap may be thin or ulcerate. Exposed to the pressure associated with blood flow, plaques, especially those with a thin lining, may rupture and trigger the formation of a blood clot (thrombus). The cholesterol crystals have been associated with plaque rupture through mechanical injury and inflammation.

=== New New Riders: 1982–1997 === From the early 1980s to the late 1990s Dawson continued as leader of the New Riders of the Purple Sage. He was joined by bluegrass-oriented multi-instrumentalist Rusty Gauthier, who sang and played acoustic guitar, slide guitar, mandolin, banjo, and fiddle. During this fifteen-year period, an evolving lineup of musicians played with Dawson and Gauthier in the New Riders. These included among others, guitarists Allen Kemp, Gary Vogensen, and Evan Morgan; bass players Fred Campbell, Bill Laymon, and Michael White; and drummers Val Fuentes, and Greg Lagardo. Some projects had the current line-up performing new material and others reworked older material. On some albums, such as Midnight Moonlight, the band's sound was less influenced by electric country rock and more by acoustic bluegrass music.

In other cases, the solid reactants do not need to be melted, but instead can react through a solid-state reaction route. In this method, the reactants are repeatedly finely ground into a paste and then heated to a temperature where the ions in neighboring reactants can diffuse together during the time the reactant mixture remains in the oven. Other synthetic routes use a solid precursor with the correct stoichiometric ratio of non-volatile ions, which is heated to drive off other species. In some reactions between highly reactive metals (usually from Group 1 or Group 2) and highly electronegative halogen gases, or water, the atoms can be ionized by electron transfer, a process thermodynamically understood using the Born–Haber cycle. Salts can be formed through a variety of reaction types, such as those between:

Sources: en.wikipedia.org

Frequently asked questions

What class of compound is this?

It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.

Why does the code PT-141 still appear?

PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.

Is intranasal use equivalent to approved use?

No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.

What does the code PT-141 refer to?

PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.

Network